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Abstract The thiazolidinone CFTRinh-172 was identi¢ed re-
cently as a potent and selective blocker of the cystic ¢brosis
transmembrane conductance regulator (CFTR) Cl3 channel.
Here, we characterized the CFTRinh-172 inhibition mechanism
by patch-clamp and short-circuit analysis using cells stably ex-
pressing wild-type and mutant CFTRs. CFTRinh-172 did not
alter CFTR unitary conductance (8 pS), but reduced open prob-
ability by s 90% with KiW0.6 WM. This e¡ect was due to
increased mean channel closed time without changing mean
channel open time. Short-circuit current experiments indicated
similar CFTRinh-172 inhibitory potency (KiW0.5 WM) for inhi-
bition of Cl3 current in wild-type, G551D, and G1349D CFTR;
however, Ki was signi¢cantly reduced to 0.2 WM for vF508
CFTR. Our studies provide evidence for CFTR inhibition by
CFTRinh-172 by a mechanism involving altered CFTR gating.
7 2004 Published by Elsevier B.V. on behalf of the Federation
of European Biochemical Societies.
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1. Introduction
The cystic ¢brosis transmembrane conductance regulator
(CFTR) is a plasma membrane Cl3 channel that is involved
in the electrolyte/£uid transport in various epithelial cells. De-
fective CFTR function causes cystic ¢brosis (CF), the most
common lethal genetic disease in caucasians that produces
severe lung disease, pancreatic insu⁄ciency, neonatal intesti-
nal obstruction, and infertility [1]. CFTR is activated by
cAMP-dependent phosphorylation at its R domain and
modulated by interaction/hydrolysis of ATP at its two nucle-
otide binding domains NBD-1 and NBD-2 [2].
We recently identi¢ed by high-throughput screening a
small-molecule CFTR inhibitor, 3-[(3-tri£uoromethyl)phen-
yl]-5-[(3-carboxyphenyl) methylene]-2-thioxo-4-thiazolidinone,
labeled CFTRinh-172 [3]. CFTRinh-172 blocked CFTR-depen-
dent Cl3 currents with KiW300 nM, nearly 500-fold more
potent than that of the reference CFTR blocker glibencla-
mide. Although CFTRinh-172 is electrically charged at phys-
iological pH, its block was not a¡ected by changes in mem-
brane potential, suggesting that its binding site does not lie in
a region that senses the transmembrane electric ¢eld. Unlike
other CFTR/Cl3 channel blockers such as diphenylamine-2-
carboxylate (DPC), 5-nitro-2(3-phenylpropyl-amino)benzoate
(NPPB), ni£umic acid, and glibenclamide, which a¡ect other
anion and cation channels [4^10], CFTRinh-172 was selective
at concentrations that strongly inhibit CFTR, without inhib-
iting Ca2þ-dependent and swelling-activated Cl3 channels, or
altering ATP-sensitive Kþ channel or MDR-1 function [3].
CFTRinh-172 was found to have favorable pharmacological
properties in rodents and was e¡ective in blocking intestinal
£uid secretion in response to cholera toxin and the heat-stable
Escherichia coli STa toxin [3,11]. CFTRinh-172 is moderately
permeable across cell membranes, as shown by its rapid onset
of inhibition [3], and across cell layers, as shown from Caco-2
permeability assays [11]. CFTRinh-172 has also been proposed
to be useful to create animal models of CF.
The mechanism underlying the block of CFTR-dependent
Cl3 currents by CFTRinh-172 is unknown, possibly involving
direct interaction with CFTR at the channel pore, the NBDs,
or the R domain. Accordingly, CFTRinh-172 may interfere
directly with Cl3 £ux through the pore or reduce the open
channel probability by altering CFTR channel gating. Other
CFTR blockers, including glibenclamide and DPC, inhibit
Cl3 currents in a voltage-dependent manner, with greater
channel inhibition at negative membrane potentials [12^15].
These compounds are thought to bind to a site on the cyto-
solic side of CFTR and behave as open channel blockers, such
that Cl3 £ux is interrupted when CFTR is open producing an
apparent decrease in mean channel open time. The aim of this
study was to elucidate the mechanism of CFTR block using
electrophysiological methods. We report evidence for a CFTR
inhibition mechanism involving altered channel gating.
2. Materials and methods
2.1. Patch-clamp experiments
Patch-clamp experiments were done at room temperature (22^24‡C)
on NIH-3T3 ¢broblasts stably expressing wild-type CFTR. Cell-at-
tached, inside-out, or whole-cell con¢gurations of the patch-clamp
technique were used [16]. The cell membrane was clamped at speci¢ed
voltages using an EPC-7 patch-clamp ampli¢er (List Medical). Data
were ¢ltered at 250 Hz and digitized at 500 Hz using an ITC-16 data
translation interface (Instrutech).
The pipette solution contained (in mM): 120 CsCl, 10 TEA-Cl, 0.5
EGTA, 1 MgCl2, 40 mannitol, 10 Cs-HEPES (pH 7.3). For whole-cell
experiments, this solution was supplemented with 0.4 or 3 mM
MgATP. The bath solution for cell-attached experiments contained
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(in mM): 130 NaCl, 2 KCl, 1 KH2PO4, 2 CaCl2, 2 MgCl2, 10 glucose,
20 mannitol, 10 Na-HEPES (pH 7.3). The bath solution for inside-out
experiments contained (in mM): 160 CsCl, 0.5 CaCl2, 2 MgCl2,
1 EGTA, 10 glucose, 10 Cs-TES, and 0.4 or 1 mM MgATP (pH
7.35). To induce CFTR phosphorylation, this solution was supple-
mented with 15 Wg/ml of the catalytic subunit of protein kinase A
(Promega). The bath solution for whole-cell experiments contained
(in mM): 150 NaCl, 1 CaCl2, 1 MgCl2, 10 glucose, 10 mannitol, 10
Na-TES (pH 7.4). CFTRinh-172 was applied in the bath solution at
the indicated concentrations. This compound is highly soluble in di-
methylsulfoxide, and soluble up to 20^30 WM in physiological saline.
In cell-attached and inside-out experiments, recordings of at least
3 min duration were analyzed. Open channel probability, Po, was
calculated as: Po = (t1+t2+Ttn)/(Nttot), where ttot is the total time,
N the number of channels, t1 the time that one or more channels
are open, t2 the time that two or more channels are open, etc. [17].
Mean channel open time was calculated as described [18]: to =gjtj /n,
where tj is the time that j channels are open at the same time, and n is
the total number of open-to-closed state transitions. Mean channel
closed time, tc, was obtained from: Po = to/(tc+to).
For whole-cell and inside-out experiments, membrane potentials are
reported using the standard convention with extracellular side of the
membrane taken as reference. For cell-attached experiments, the
extracellular bath is taken as reference. Preliminary experiments in-
dicated that CFTR currents and block by CFTRinh-172 were not
a¡ected by membrane potential (not shown). Therefore, cell-attached
experiments were generally done at a single pipette potential (+60
mV). Whole-cell membrane currents were recorded by stepping the
membrane potential from +80 to 3100 mV starting from a holding
potential of 35 mV. Inside-out experiments were performed at a
membrane potential of 360 mV.
2.2. Short-circuit current
Fischer rat thyroid (FRT) cells expressing wild-type or mutant
CFTRs were plated on Snapwell inserts (Corning Costar) as described
[3]. After 7^9 days, inserts were mounted in a vertical di¡usion cham-
ber (Corning Costar). The basolateral chamber was ¢lled with a so-
lution containing (in mM): 130 NaCl, 2.7 KCl, 1.5 KH2PO4, 1 CaCl2,
0.5 MgCl2, 10 Na-HEPES (pH 7.3) and 10 glucose. For the apical
side, this solution was modi¢ed by replacing half of NaCl with Na
gluconate and increasing CaCl2 to 2 mM to compensate for calcium
bu¡ering caused by gluconate. Both hemichambers were bubbled with
air and the temperature maintained at 37‡C. The basolateral mem-
brane was permeabilized with 250 Wg/ml amphotericin B. Short-circuit
current was recorded with a DVC-1000 voltage clamp (World Preci-
sion Instruments) using Ag/AgCl electrodes and 1 M KCl agar
bridges.
3. Results
Cell-attached patch recordings were performed on NIH-3T3
¢broblasts expressing wild-type CFTR. Little channel activity
was detected under resting conditions. Addition of 5 WM for-
skolin to the bath resulted in multiple channel openings (two
to six per patch) having a voltage-independent single-channel
conductance of 8 pS as reported previously for CFTR. Addi-
tion of CFTRinh-172 to the perfusate in the continued pres-
ence of forskolin did not change unitary conductance, but
reduced channel activity markedly as seen by the less frequent
channel openings (Fig. 1A) and the all-point histograms (Fig.
1A, right). Fig. 1B summarizes open channel probability (Po)
measured at di¡erent CFTRinh-172 concentrations, showing a
dose-dependent decrease in Po with Ki of 0.57 WM and Hill
coe⁄cient, nH, of 0.83.
To clarify the basis for the change in Po, mean channel
open and closed times were measured at di¡erent CFTRinh-
172 concentrations (Fig. 1C). Interestingly, mean channel
open time was not changed whereas the mean channel closed
time was signi¢cantly prolonged in a dose-dependent manner.
At 2 WM CFTRinh-172 mean channel closed time increased
from 0.6 to 4.2 s whereas mean channel open time remained
V0.3 s. CFTR is characterized by two di¡erent closure
events: brief intraburst closures and long-lasting interburst
closures. When the results were reanalyzed by ignoring the
closures below 30 ms, CFTRinh-172 still increased closed
time without a¡ecting open time. For example, tc increased
from 3.3Q 0.3 to 17Q 2 s in the presence of 2 WM CFTRinh-
172 (P6 0.01; not shown), whereas to did not change signi¢-
cantly (1.3 Q 0.1 vs. 1.1 Q 0.2). Thus CFTRinh-172 inhibits
CFTR by an altered channel gating mechanism.
Similar measurements were done using the known (though
relatively less potent and speci¢c) CFTR blocker glibencla-
mide. At 100 WM, a glibenclamide concentration that partially
blocked CFTR, frequent fast closures were seen, with a s 10-
fold decrease in apparent mean open time (Fig. 2). This be-
havior contrasts sharply with the CFTRinh-172 inhibition
mechanism.
Cell-detached patch-clamp experiments were done using the
inside-out con¢guration to assess CFTRinh-172 e⁄cacy under
cell-free conditions and to test whether ATP is competitive
with the CFTRinh-172 block. After patch excision, channel
openings were not observed prior to CFTR activation (Fig.
3A). Multiple channel openings were seen after bath (cytosolic
Fig. 1. Block of CFTR currents in cell-attached patches. A: Repre-
sentative recordings from a cell-attached patch-clamp experiment
showing CFTR channel activity with and without CFTRinh-172 in
the bath (extracellular) solution. Dashed lines show zero current lev-
el (channels closed) with downward de£ections indicating channel
openings. Pipette potential was +60 mV. All-point histograms are
shown on the right of each trace. Note the decrease in the areas of
peaks corresponding to multiple channel levels. B: Open channel
probability (Po) versus inhibitor concentration with ¢tted Ki 0.57Q
0.06 WM and Hill coe⁄cient 0.83Q 0.07. C: Mean channel open
(top) and closed (bottom) times versus CFTRinh-172 concentration
( QS.E.M., n=3^5). Asterisks indicate a signi¢cant di¡erence (P6
0.01) compared to no inhibitor.
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side) application of the catalytic subunit of protein kinase A
and ATP. Addition of CFTRinh-172 produced a reversible
decrease in channel activity similar to that observed in cell-
attached recordings. Additional inside-out patch-clamp ex-
periments were done to test for ATP competition using two
concentrations of CFTRinh-172 (0.2 and 1 WM) and ATP (0.4
or 1 mM) in the bath (cytosolic) solution. The decrease in Po
caused by CFTRinh-172 was not dependent on ATP concen-
tration (Fig. 3B). Similar results were obtained using the
whole-cell patch-clamp con¢guration using speci¢ed pipette
solutions to set cytoplasmic ATP concentration. The dose
response for CFTRinh-172 inhibition of CFTR Cl3 current
was not di¡erent at 0.4 and 3 mM concentrations of ATP
in the pipette solution (Fig. 3C). These results indicate that
CFTRinh-172 interacts directly with CFTR, and that
CFTRinh-172 and ATP do not compete.
To test whether CFTRinh-172 interacts with one of the
NBDs, we compared the inhibitory potency of CFTRinh-172
on wild-type CFTR and the mutants G551D and G1349D
that produce defective CFTR gating NBD-1 and NBD-2, re-
spectively. Transfected FRT cells were studied in short-circuit
current experiments. After activating wild-type CFTR using a
high concentration of cpt-cAMP, CFTRinh-172 blocked the
resulting Cl3 current in a dose-dependent manner, with a Ki
of 0.37 WM (nH = 0.92) (Fig. 4). The £avone genistein (at 200
WM) together with cpt-cAMP was used to maximally activate
the CFTR mutants G551D and G1349D. CFTRinh-172
blocked G551D and G1349D Cl3 currents with potency not
signi¢cantly di¡erent from that for inhibition of wild-type
CFTR, with Ki of 0.53 WM (nH = 0.90) and 0.51 (nH = 1.17),
respectively, for G551D and G1349D (Fig. 4B,C). To test
Fig. 2. Glibenclamide inhibition of CFTR. Representative cell-at-
tached experiment showing the e¡ect of extracellular perfusion with
100 WM glibenclamide. In contrast to CFTRinh-172, glibenclamide
caused a marked increase in the frequency of brief closures that in-
terrupt the bursts of channel openings. Apparent mean open time
decreased from 573 to 48 ms. Pipette potential was +60 mV.
Fig. 3. CFTRinh-172 inhibition in excised membrane patches and
ATP dependence. A: Representative traces from an excised inside-
out patch showing no basal activity, multiple channel openings after
bath (cytosolic) application of catalytic subunit of protein kinase A
(15 Wg/ml) and ATP (1 mM), decreased channel activity after
CFTRinh-172, and recovery after inhibitor wash-out. B: Inhibition
of open channel probability in inside-out patches as a function of
CFTRinh-172 concentration (0.2 and 1 WM) and ATP concentration
(0.4 and 1 mM). Di¡erences not signi¢cant. C: Dose responses for
CFTRinh-172 inhibition in whole-cell experiments with 0.4 or 3 mM
ATP in the pipette (intracellular solution) and membrane potential
clamped at +80 mV (S.E.M., n=4^5). Inset: Representative whole-
cell membrane currents elicited at +80 mV with and without
CFTRinh-172. The same dose response was obtained by clamping
the membrane potential at 3100 mV (not shown).
Fig. 4. Sensitivity of CFTR mutants to inhibition by CFTRinh-172.
A: Representative short-circuit current experiments on permeabilized
FRT cells expressing wild-type CFTR, or G551D, G1349D, and
vF508 mutants. cpt-cAMP concentration was 100 WM and genistein
concentrations were 50 WM (wild-type and vF508) or 200 WM
(G551D and G1349D). Cells expressing vF508-CFTR were incuba-
ted at 27‡C for 24 h prior to measurements to rescue the mutant
protein from the endoplasmic reticulum [19]. B: CFTRinh-172 dose^
response curves. C: Kd obtained by ¢tting dose^response curves
(S.E.M., n=5^8). *P6 0.01 and 0.05 compared to wild-type CFTR
with and without genistein, respectively.
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whether CFTR activation by genistein could alter CFTRinh-
172 potency, a CFTRinh-172 dose response was done on wild-
type CFTR after activation with 50 WM genistein (the max-
imal possible concentration on the wild-type protein since
higher concentrations induce inhibition). After genistein acti-
vation, the CFTRinh-172 inhibitory potency did not di¡er sig-
ni¢cantly (Ki = 0.48; nH = 0.96) from that measured for
G551D and G1349D. Thus, these gating mutants were not
informative in de¢ning the location of the putative
CFTRinh-172 binding site on CFTR. Therefore, we also tested
the e⁄cacy of CFTRinh-172 in cells expressing vF508-CFTR
(after low temperature rescue [19]), the most frequent muta-
tion in CF subjects. Interestingly, vF508-CFTR Cl3 currents
were inhibited by CFTRinh-172 with a signi¢cant about two-
fold greater e⁄cacy than found for wild-type CFTR and the
G551D and G1349D mutants (Fig. 4B,C). This ¢nding sug-
gests CFTRinh-172 interaction at the CFTR NBD-1 domain.
4. Discussion
The purpose of this study was to de¢ne the CFTR inhibi-
tion mechanism of the thiazolidinone CFTRinh-172, a small
molecule CFTR inhibitor identi¢ed recently by high-through-
put screening of a collection of diverse small molecules [3].
CFTRinh-172 was substantially more potent and CFTR-selec-
tive than the existing Cl3 channel blockers glibenclamide,
NPPB, ni£umic acid, and DPC. We reported previously that
CFTRinh-172 strongly blocked CFTR currents in Ussing
chamber and whole-cell patch-clamp experiments, and that
the CFTRinh-172 block was not a¡ected by the applied mem-
brane potential [3]. However, the mechanism of CFTRinh-172
block was not characterized, nor was its possible site of inter-
action on the CFTR molecule.
We found here in cell-attached recordings that CFTRinh-
172 strongly reduced open channel probability without a¡ect-
ing single channel conductance. Interestingly, CFTRinh-172
increased the time that the channel spends in the closed state
without a¡ecting mean open time. This inhibition mechanism
contrasts with other known CFTR blockers, including gliben-
clamide and DPC, which are open channel blockers [12^15].
Open channel blockers decrease mean channel open time by a
mechanism that may involve plugging into the channel pore
and interrupting anion £ux. The increase in mean CFTR
channel closed time after CFTRinh-172 indicates modi¢cation
of channel gating rather than block of the channel conductive
pathway. This conclusion is in agreement with the ¢nding that
CFTRinh-172 block, in contrast to glibenclamide and DPC
[12^15], is not a¡ected by the transmembrane voltage despite
its negative charge. Therefore, the CFTRinh-172 binding site
probably does not lie close to the pore in a region sensitive to
the transmembrane electrical ¢eld, bur rather in a structure
that controls channel gating. The alteration of CFTR gating
by CFTRinh-172 resembles that described for genistein [17,18].
Although at low micromolar concentrations genistein is a
CFTR activator, at high micromolar concentrations genistein
decreases Po due to a prolongation of the closed time.
Changes in CFTR mean closed time have also been reported
for electrolyte-dependent variations in Po [20].
One hypothesis to explain CFTRinh-172 inhibition is im-
pairment of CFTR channel gating by binding to one of the
NBDs, possibly by interfering with ATP/NBD interactions.
However, in inside-out and whole-cell patch-clamp experi-
ments there was no e¡ect of ATP concentration on the e⁄-
cacy of the CFTRinh-172 block thus indicating that the thia-
zolidinone blocker does not compete with ATP for binding to
either NBD.
We also tested the e¡ect of CFTR mutations that impair
NBD function and thus reduce CFTR opening, including
G551D and G1349D. Such mutations are localized in NBD-
1 and NBD-2, respectively, and have been shown to impair
ATP binding [21,22]. CFTRinh-172 had comparable inhibitory
potency for reducing Cl3 currents for wild-type CFTR,
G551D, and G1349D. This ¢nding supports the conclusion
that CFTRinh-172 does not act by interfering with ATP bind-
ing at CFTR NBDs. However, remarkably, the CFTRinh-172
Ki was signi¢cantly reduced for the CFTR mutant vF508,
suggesting that CFTRinh-172 may interact with a speci¢c
site on the NBD-1 domain of CFTR where the vF508 muta-
tion resides, though allosteric e¡ects on other protein domains
cannot be excluded. It has been reported that the vF508 pro-
tein has a decreased open channel probability due to longer
permanence in a closed state [23,24]. Therefore, the vF508
mutant has a defective conformation and function also
when targeted to the plasma membrane by cell incubation
at low temperature. It is possible that CFTRinh-172 has great-
er a⁄nity to the speci¢c protein conformation generated by
the vF508 mutation.
In conclusion, our study shows that the thiazolidinone
CFTRinh-172 behaves di¡erently from other known blockers
of the CFTR channel. Rather than blocking the channel pore,
it a¡ects the mechanism of channel gating, possibly by bind-
ing to NBD-1. In addition to its potential applications as an
antidiarrheal agent and in creating the CF phenotype,
CFTRinh-172 could thus be a useful tool to investigate the
molecular mechanisms underlying CFTR function and regu-
lation.
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